Arvinas

-$0.44 (-1.07%) Today
$0.00 (0.00%) As of 8:00 PM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Arvinas and other ETFs, options, and stocks.

About ARVN

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.

CEO
John G. Houston
Employees
280
Headquarters
New Haven, Connecticut
Founded
2013

ARVN Key Statistics

Market cap
2.17B
Price-Earnings ratio
—
Dividend yield
—
Average volume
468.47K
High today
$41.50
Low today
$39.98
Open price
$41.00
Volume
409.70K
52 Week high
$108.47
52 Week low
$37.41

ARVN News

BenzingaMay 20

Analyst Ratings for Arvinas

Arvinas ARVN has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3

ARVN Earnings

-$1.20
-$0.03
$1.13
$2.30
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Estimated
— per share
Actual
Expected Aug 4, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure